Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Jul;11(4):e1552. doi: 10.1002/wnan.1552. Epub 2019 Feb 7.
"Off the shelf" allogeneic stem cell transplants and stem cell nano-composites are being used for the treatment of degenerative bone diseases. However, major and minor histocompatibility antigens of therapeutic cell transplants can be recognized as foreign and lead to their rejection by the host immune system. If a host immune response is identified within the first week post-transplant, immune modulating therapies could be applied to prevent graft failure and support engraftment. Ferumoxytol (Feraheme™) is an FDA approved iron oxide nanoparticle preparation for the treatment of anemia in patients. Ferumoxytol can be used "off label" as an magnetic resonance (MR) contrast agent, as these nanoparticles provide measurable signal changes on magnetic resonance imaging (MRI). In this focused review article, we will discuss three methods to localize and identify innate immune responses to stem cell transplants using ferumoxytol-enhanced MRI, which are based on tracking stem cells, tracking macrophages or detecting mediators of cell death: (a) monitor MRI signal changes of ferumoxytol-labeled stem cells in the presence or absence of innate immune responses, (b) monitor influx of ferumoxytol-labeled macrophages into stem cell implants, and (c) monitor apoptosis of stem cell implants with caspase-3 activatable nanoparticles. These techniques can detect transplant failure at an early stage, when immune-modulating interventions can potentially preserve the viability of the cell transplants and thereby improve bone and cartilage repair outcomes. Approaches 1 and 2 are immediately translatable to clinical practice. This article is categorized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging Nanotechnology Approaches to Biology > Cells at the Nanoscale Diagnostic Tools > Biosensing.
“现成的”异体干细胞移植和干细胞纳米复合材料正被用于治疗退行性骨疾病。然而,治疗性细胞移植的主要和次要组织相容性抗原可能被宿主免疫系统识别为外来物,导致其被排斥。如果在移植后第一周内识别出宿主免疫反应,则可以应用免疫调节疗法来防止移植物衰竭并支持植入。Ferumoxytol(Feraheme)是一种获得 FDA 批准的氧化铁纳米颗粒制剂,用于治疗贫血患者。Ferumoxytol 可以“超适应证”用作磁共振(MR)造影剂,因为这些纳米颗粒在磁共振成像(MRI)上可提供可测量的信号变化。在这篇重点综述文章中,我们将讨论三种使用 Ferumoxytol 增强 MRI 定位和识别干细胞移植固有免疫反应的方法,这些方法基于跟踪干细胞、跟踪巨噬细胞或检测细胞死亡的介质:(a)监测存在或不存在固有免疫反应时 Ferumoxytol 标记干细胞的 MRI 信号变化,(b)监测 Ferumoxytol 标记的巨噬细胞流入干细胞植入物,(c)使用半胱天冬酶-3 激活的纳米颗粒监测干细胞植入物的细胞凋亡。这些技术可以在早期检测到移植失败,此时免疫调节干预可能有潜力维持细胞移植的活力,从而改善骨和软骨修复结果。方法 1 和 2 可以立即转化为临床实践。本文属于以下类别:诊断工具 > 体内纳米诊断和成像 纳米技术方法生物学 > 纳米尺度的细胞 诊断工具 > 生物传感。